Overview
How do countries across the globe collaborate effectively in delivering innovative pharmaceutical products, medical devices, and regenerative medical products to patients, in the fastest and most efficient way possible? With healthcare product development becoming increasingly global, the time has come to deepen the discussion on how to leverage the individual strengths of countries, promote better collaboration, and strengthen global partnerships, in order to build the ideal ecosystem for creating medicines, medical devices, and regenerative medical products.
Furthermore, innovative technologies such as artificial intelligence (AI), big data/genomics, and cell/gene therapies are poised to transform healthcare product development across the globe – join us at the DIA Japan Annual Meeting 2018, to discuss these topics and the future of healthcare!
Our two invited keynote speakers will be Professor Guido Rasi, Executive Director of the European Medicines Agency (EMA) and Professor Satoru Miyano of Tokyo University, a leading expert in the fields of genome informatics and AI. On day one of our agenda, our first DIA Japan Annual Meeting innovative DIAmond session will be convened by members of the “Innovation Project” led by The International Coalition of Medicines Regulatory Authorities (ICMRA). Our second DIAmond Session, Innovative Clinical Trials, will be led by top leaders from industry, government, and academia, and share their expert insights into clinical trials of the future in the evolving contexts of innovative technologies and environmental changes. General sessions will address other critical “hot topics,” and the meeting also features our popular PMDA Town Hall Meeting and special chat session.
We look forward to welcoming you at Tokyo Big Sight from November 11-13, 2018 for stimulating discussions around promoting better collaboration to drive global health and innovation in this era of medical and scientific transformation.
We hope to see you there!
Program Committee
-
Takuko Sawada • Director of the Board, Executive Vice President
Shionogi & Co., Ltd., Japan -
Kazuhiro Kanmuri, PhD • Founder & CEO
Inter-Professional Inc., Japan -
Taro Amagasaki, PhD • Department Head, Integrated Biostatistics Japan Department
Novartis Pharma K.K., Japan -
Noriko Fujiwara, MS, RN • Research Nurse, Project Researcher, Department of Palliative Medicine
IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan -
Yoshikata Furuya, MSc • Director, Vaccine Policy, Health Policy
MSD K.K., Japan -
Shinzo Hiroi, PhD, MPH, RPh, PMP • Head of Global Medical Affairs
Shionogi & Co., Ltd., Japan -
Kazuo Ichikawa, PhD, PMP • Senior Staff Adviser, Group II, Global Project Management Department, R&D Div.
Daiichi Sankyo Co., Ltd., Japan -
Katsuhiko Ichimaru • Deputy Director for MID-NET project
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Akiko Ikeda, RPh • Senior Manager, Policy Intelligence Dept., Integrated Market Access Division
Janssen Pharmaceutical K.K., Japan -
Toshiko Ishibashi, PhD, RN • Clinical Operation I, JAPAN, Clinical Operation
Ono Pharmaceutical Co., Ltd., Japan -
Kazuhiko Ishida, MSc, RPh • Risk Management Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Miyuki Kaneko • Manager, Japan Regulatory Lead
Pfizer Japan Inc., Japan -
Yoko Kazami, PMP • Manager
Nobelpharma Co., Ltd., Japan -
Noriatsu Kono, MPharm • Managing Director, Department of Innovative Drug Discovery and Development
Japan Agency for Medical Research and Development (AMED), Japan -
Yukihiro Matsuda, MSc • Research Scientist, Trial Mgmt., Clinical Development Operations & Innovatiion
Eli Lilly Japan K.K., Japan -
Yasutsugu Nakano • Sr. Director, Head of Development Regulatory Affairs 2, Regulatory Affairs Dept.
Shionogi & Co., Ltd., Japan -
Motohide Nishi, MBA • Vice President, Asia Pacific Technology
Medidata Solutions K.K., Japan -
Minori Niso • Acute Care Diagnostics Product Manager, Instrumentation Laboratory
I.L. Japan Co., Ltd., Japan -
Atsushi Noguchi, MS • Reviewer, Office of New Drug V
Pharmaceuticals and Medical Devices Agency, Japan -
Kimiya Okazaki, PharmD, PhD • Associate Department Manager, Regulatory Intelligence, Regulatory Affairs
GlaxoSmithKline K.K., Japan -
Mikiko Shitara • Manager, Labeling Group, RA Management, RA, Development & Medical Affairs Div.
GlaxoSmithKline K.K., Japan -
Kuniko Shoji •
The Japan Society for the Promotion of Machine Industry, Japan -
Keiko Tsumori • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Tadashi Urashima, PhD • Manager (Strategy Deployment and Digital Practices), MA Excellence Dept.
GlaxoSmithKline K.K., Japan -
Koichiro Yuji, MD, PhD, FACP • Project Associate Professor, The Institute of Medical Science
The University of Tokyo, Japan -
Junichi Nishino, MSc, RPh • Head, RA Functions Department, Regulatory Office Japan
Novartis Pharma K.K., Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Atsushi Tsukamoto, PhD • Vice President, New Drug Regulatory Affairs
Daiichi Sankyo Co., Ltd., Japan
